{"id":"placebo-for-azilsartan-medoxomil","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials to establish the efficacy of the active drug (azilsartan medoxomil) through comparison. It contains no active pharmaceutical ingredient and produces no direct therapeutic effect beyond potential placebo response.","oneSentence":"This is a placebo control with no active pharmacological mechanism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:27.839Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in phase 3 trials for azilsartan medoxomil (angiotensin II receptor antagonist for hypertension)"}]},"trialDetails":[{"nctId":"NCT02235909","phase":"PHASE3","title":"An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension","status":"COMPLETED","sponsor":"Arbor Pharmaceuticals, Inc.","startDate":"2015-03-30","conditions":"Hypertension","enrollment":377},{"nctId":"NCT02791438","phase":"PHASE3","title":"A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-08-18","conditions":"Pediatric Hypertension","enrollment":27},{"nctId":"NCT02480764","phase":"PHASE3","title":"Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-08-27","conditions":"Essential Hypertension","enrollment":612},{"nctId":"NCT01774591","phase":"NA","title":"Effect of Azilsartan on Aldosterone in Postmenopausal Females","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2013-01","conditions":"Hypertension","enrollment":21},{"nctId":"NCT02203916","phase":"PHASE3","title":"Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-07","conditions":"Hypertension","enrollment":328},{"nctId":"NCT01496430","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes","status":"TERMINATED","sponsor":"Takeda","startDate":"2012-01","conditions":"Hypertension, Diabetes","enrollment":105},{"nctId":"NCT01456169","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-10","conditions":"Essential Hypertension","enrollment":507},{"nctId":"NCT02072330","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-03","conditions":"Grade I or II Essential Hypertension","enrollment":353},{"nctId":"NCT00846365","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-03","conditions":"Essential Hypertension","enrollment":1085},{"nctId":"NCT00762736","phase":"PHASE2","title":"Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2004-07","conditions":"Diabetes Mellitus","enrollment":704},{"nctId":"NCT00818883","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-02","conditions":"Essential Hypertension","enrollment":609},{"nctId":"NCT00847626","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-01","conditions":"Hypertension","enrollment":1711},{"nctId":"NCT01033071","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-01","conditions":"Essential Hypertension","enrollment":1071},{"nctId":"NCT00696384","phase":"PHASE3","title":"A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-06","conditions":"Hypertension","enrollment":418},{"nctId":"NCT00696241","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-06","conditions":"Hypertension","enrollment":1275},{"nctId":"NCT00591266","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-10","conditions":"Hypertension","enrollment":566},{"nctId":"NCT00591773","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-09","conditions":"Hypertension","enrollment":551},{"nctId":"NCT00591253","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-10","conditions":"Hypertension","enrollment":413},{"nctId":"NCT00696436","phase":"PHASE3","title":"An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-04","conditions":"Hypertension","enrollment":1291},{"nctId":"NCT00362115","phase":"PHASE2","title":"Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-05","conditions":"Hypertension","enrollment":449},{"nctId":"NCT01289132","phase":"PHASE2","title":"Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-07","conditions":"Essential Hypertension","enrollment":926},{"nctId":"NCT00376181","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Takeda","startDate":"2006-06","conditions":"Type 2 Diabetes","enrollment":96},{"nctId":"NCT00759551","phase":"PHASE2","title":"Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2004-08","conditions":"Hypertension","enrollment":555}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for Azilsartan Medoxomil","genericName":"Placebo for Azilsartan Medoxomil","companyName":"Arbor Pharmaceuticals, Inc.","companyId":"arbor-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control with no active pharmacological mechanism. Used for Control arm in phase 3 trials for azilsartan medoxomil (angiotensin II receptor antagonist for hypertension).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}